Kamada (NASDAQ:KMDA) Announces Quarterly Earnings Results

Kamada (NASDAQ:KMDA) posted its quarterly earnings data on Wednesday. The biotechnology company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05), FiscalAI reports. The company had revenue of $45.24 million during the quarter, compared to the consensus estimate of $46.72 million. Kamada had a net margin of 11.19% and a return on equity of 7.72%.

Here are the key takeaways from Kamada’s conference call:

• Kamada reiterated full-year 2026 guidance for $200 million-$205 million in revenue and $50 million-$53 million in adjusted EBITDA, saying the outlook is based on organic growth only and implies stronger results in the back half of the year.
• First-quarter revenue was $42.5 million, up 3% year over year, with growth driven mainly by KEDRAB and the distribution segment. A temporary shipment delay reduced Q1 revenue by about $2.4 million, but the order was already delivered in April.
• Management said demand remains strong for key products, especially KEDRAB, which is seeing increased end-user utilization in the U.S. and international markets, and VARIZIG, which is benefiting from product awareness and more chickenpox outbreaks.
• The company is expanding its distribution and biosimilars business, with two additional biosimilars expected to launch in Israel by late Q2/early Q3 and a target of roughly 45 products in the Israeli portfolio by year-end. Management also expects biosimilar sales could reach $15 million-$20 million annually over the next four to five years.
• Kamada said its newly FDA-approved San Antonio plasma center is cleared to begin commercial normal source plasma sales in the second half of 2026, and both the Houston and San Antonio centers are expected to reach planned capacity toward end-2027/early-2028. The company also noted it remains active on business development and M&A to add products and synergies.

Kamada Trading Up 2.0%

Shares of NASDAQ:KMDA traded up $0.16 during trading on Thursday, hitting $8.02. 68,031 shares of the company were exchanged, compared to its average volume of 68,498. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The stock has a market cap of $461.23 million, a price-to-earnings ratio of 22.91, a P/E/G ratio of 0.64 and a beta of 0.86. The firm has a fifty day moving average price of $8.44 and a two-hundred day moving average price of $7.88.

Kamada Announces Dividend

The business also recently declared an annual dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a $0.25 dividend. This represents a yield of 305.0%. The ex-dividend date was Monday, March 23rd. Kamada’s dividend payout ratio (DPR) is currently 54.29%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Benchmark restated a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Wall Street Zen cut shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus set a $11.00 target price on shares of Kamada in a report on Wednesday, March 11th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $13.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Barclays PLC increased its position in Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 3,862 shares during the period. XTX Topco Ltd acquired a new position in Kamada during the 4th quarter worth approximately $103,000. SIH Partners LLLP acquired a new position in shares of Kamada during the fourth quarter worth $134,000. Quadrature Capital Ltd raised its position in Kamada by 53.5% in the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 7,627 shares during the last quarter. Finally, Man Group plc bought a new position in Kamada in the 3rd quarter valued at approximately $199,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.